Using a virus to treat lymphoma
Intravenous VSV virotherapy in lymphoma
This study is testing a new virus treatment for people with relapsed T cell lymphoma to see if it can safely target and kill cancer cells while sparing healthy ones, and it will also look at how well it works when combined with other immune therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11083746 on NIH RePORTER |
What this research studies
This research investigates a new treatment for relapsed refractory T cell lymphoma using an engineered virus called VSV-IFNβ-NIS. The virus is designed to selectively target and destroy cancer cells while leaving healthy cells unharmed. Patients will receive a single intravenous infusion of the virus, and the study aims to enhance treatment effectiveness by combining it with immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 antibodies. The goal is to improve patient responses and the duration of those responses to the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed refractory T cell lymphoma who have not responded to previous treatments.
Not a fit: Patients with early-stage lymphoma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with difficult-to-treat lymphoma.
How similar studies have performed: Previous studies have shown promising results with similar virotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Peng, Kah-Whye — Mayo Clinic Rochester
- Study coordinator: Peng, Kah-Whye
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.